Back to Directory

Charlotte Perlowski

Email

cperlowski@fhi360.org

Phone

919-321-3581

Institution

FHI 360

Title

Clinical Research Manager

Address

FHI 360
359 Blackwell St.
Suite 200
Durham, NC 27701
United States of America

Request an Update

Affiliated Studies

IMPAACT 2008: Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants

DAIDS Number

Research Area

Cure and Immunotherapy

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

DAIDS Number

Research Area

Cure and Immunotherapy

Study Status

Closed to Accrual

P1112: Monoclonal Antibody PK Study

DAIDS Number

Research Area

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2011: Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID delta M2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

DAIDS Number

Research Area

Complications & Comorbidities

Study Status

Show All